

Theranostics: Global Markets

Market Research Report | 2024-08-05 | 118 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.

Report Includes:

- 45 data tables and 37 additional tables
- An overview of the global markets for theranostics
- Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
- Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
- Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
- Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
- A discussion of ESG challenges and ESG practices in the industry
- Analysis of the key companies' market shares, proprietary technologies and strategic alliances
- Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.

Executive Summary

Summary:

Theranostics is a combination of therapeutics and diagnostics. The main aim of theranostics is to provide diagnostics and therapeutics together in order to personalize treatment. The term was first coined by John Funkhouser in 1998. Theranostics is a prime example of personalized medicine. Radiotheranostics are applied via radionuclides, as they have properties for diagnosis and therapeutics. The primary application of theranostics is in the field of oncology.

The theranostics market is relatively new, being only about two decades old. A significant driver for theranostics is the inherent disadvantages of conventional cancer treatment. Chemotherapy has been the most widely used form of cancer treatment and is the first line of treatment for many cancers. However, chemotherapy has many disadvantages, such as adverse effects on healthy cells, loss of effectiveness on cancer cells and lack of a way to provide personalized treatment. With the help of theranostics, customized treatment can be provided to the patient, which helps overcome chemotherapy's limitations and side effects.

One of the major factors driving the theranostics market is the rising number of cancer cases in both developed and developing countries. Cancer cases are on the rise in developed countries due to the population aging and earlier and more effective screening. In contrast, cancer cases are increasing in developing countries due to growth in overall population and changing lifestyles. On the other hand, the cancer mortality rates have been declining in many regions and countries. The declining mortality rates are due to advancements in cancer treatment and early detection. Nonetheless, the rising number of cancer patients will lead to a demand for new and better technology that effectively treats the disease and improves patients' quality of life. This is possible through theranostics.

The market is faced with challenges and restraints that are holding the market back. One of the significant challenges of theranostics is the cost of treatment. Theranostics employs high-end equipment and reagents. Compared to other cancer treatments, the cost of theranostics procedures can be very high due to the involvement of many experts. It is one of the significant reasons for slow adoption, particularly in cost-sensitive markets.

Another challenge is the failure of some early radiotherapeutics. The current theranostics market is based on radionuclides. Commercial failure of these drugs has significantly hindered the market's growth. Investors may be hesitant due to a lack of return on investments.

The major opportunity in the market is for treating cancer, particularly prostate cancer and neuroendocrine tumors. Theranostics can also be applied to other cancers. Radionuclides are conjugated with antibodies, proteins and other biomarkers to achieve targeted radionuclide therapy.

Table of Contents:

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Summary
Chapter 2 Market Overview
Overview
PESTLE Analysis
Political
Economic
Social
Technological
Legal
Environmental
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Competition in the Industry
Threat of Substitutes
R&D and Regulatory Approval
The Drug Development Process
Drug Discovery
Preclinical Development
Clinical Trials
The New Drug Application Review
NDA Data Review
Clinical Trials for Theranostics
Steps Followed for Radiotherapeutics in Clinical Trials
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Theranostics Replacing Conventional Treatment
Increased Application of Theranostics in Drug Discovery
Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
New Radiotheranostics Driving the Theranostics Market
Rise in Chronic Inflammatory Diseases
Cancer Epidemics in Developing Countries
Market Restraints
High Cost of Theranostics
Market Challenges
Nanotheranostics-Bio Interactions
Challenges of Radiotheranostics
Failure of Radiotherapeutics
Market Opportunities
Theranostics in Cardiovascular Diseases
Chapter 4 Emerging Technologies and Developments
Artificial Intelligence in Theranostics
Drug Delivery Using Innovative Material
Boron Neutron Capture Therapy (BNCT)
Luminogen Aggregation-Induced Emission (AIE)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Theranostics in Rheumatoid Arthritis (RA)
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Product Type
Theranostics Equipment
Theranostics Agents
Diagnostics Theranostics Agents
Therapeutics Theranostics Agents
Market Analysis, by Application
Etiology of Cancer
Cancer Diagnosis
Cancer Therapeutics
Prostate Cancer
Neuroendocrine Tumors
Thyroid Cancer
Neuroblastoma
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Strategic Analysis
Clinical Trials Analysis
Chapter 7 Sustainability in Theranostics Market: An ESG Perspective
Introduction to ESG
Key ESG Issues in the Theranostics Market
Safety of Personnel
Disposal of Radioactive Waste
Nanopollution
Current Status of ESG in the Theranostics Market
ESG Performance Analysis
Concluding Remark from BCC Research
Chapter 8 Appendix
Methodology
Sources
Acronyms
Company Profiles
BAYER AG
CURIUM PHARMA
GE HEALTHCARE
LANTHEUS
NOVARTIS AG
SIEMENS HEALTHINEERS AG
TELIx PHARMACEUTICALS LTD.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Theranostics: Global Markets

Market Research Report | 2024-08-05 | 118 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com